OCT macular changes in type 1 ROP following Ranibizumab injections
Abstract Aim To investigate the OCT macular changes in type 1 ROP one month following Ranibizumab injections. Methods Preterm infants with type 1 ROP indicated for Ranibizumab injections were included in this study. Handheld OCT imaging was performed at baseline, 1 week, and 1 month post injection....
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | International Journal of Retina and Vitreous |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40942-025-00664-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850181336713658368 |
|---|---|
| author | Rawan Hosny Jylan Gouda Tamer A. Macky Ayman Khattab Hany Mekkawy Abdussalam M. Abdullatif |
| author_facet | Rawan Hosny Jylan Gouda Tamer A. Macky Ayman Khattab Hany Mekkawy Abdussalam M. Abdullatif |
| author_sort | Rawan Hosny |
| collection | DOAJ |
| description | Abstract Aim To investigate the OCT macular changes in type 1 ROP one month following Ranibizumab injections. Methods Preterm infants with type 1 ROP indicated for Ranibizumab injections were included in this study. Handheld OCT imaging was performed at baseline, 1 week, and 1 month post injection. Central full thickness (CFT), inner retinal layer (IRL), and outer retinal layer (ORL) thickness measurements were taken from foveal center and parafoveal region. Results 24 eyes of 12 infants were included in this study. There were no significant changes in the mean CFT and IRL thickness at 1 month (p = 0.5 and 0.1 respectively). However, there was significant increase in the mean ORL thickness at 1 month (69.9 ± 16, 96.1 ± 25 at baseline and one month respectively, p < 0.001), with differentiation (appearance of IS/OS junction ± ELM) in 55.6% of eyes. Macular edema (ME) was observed in 12 eyes (50%) and was associated with smaller birth weight (p = 0.0290). There was no significant decrease in mean CFT in eyes with ME at 1 month (p = 0.13), with complete resolution in only 6 eyes (50%) during the study period. Regression of plus was associated with lower CFT (1 week and 1 month; p = 0.02 and 0.03, respectively). Conclusion Ranibizumab treated eyes in type 1 show ORL thickening and differentiation but with inadequate resolution of ME. |
| format | Article |
| id | doaj-art-7a030183ebe44b009e181af65548c7cd |
| institution | OA Journals |
| issn | 2056-9920 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | International Journal of Retina and Vitreous |
| spelling | doaj-art-7a030183ebe44b009e181af65548c7cd2025-08-20T02:17:56ZengBMCInternational Journal of Retina and Vitreous2056-99202025-04-011111910.1186/s40942-025-00664-7OCT macular changes in type 1 ROP following Ranibizumab injectionsRawan Hosny0Jylan Gouda1Tamer A. Macky2Ayman Khattab3Hany Mekkawy4Abdussalam M. Abdullatif5Department of Ophthalmology, Kasr AlAiny Hospital, Cairo UniversityDepartment of Ophthalmology, Kasr AlAiny Hospital, Cairo UniversityDepartment of Ophthalmology, Kasr AlAiny Hospital, Cairo UniversityDepartment of Ophthalmology, Kasr AlAiny Hospital, Cairo UniversityDepartment of Ophthalmology, Kasr AlAiny Hospital, Cairo UniversityDepartment of Ophthalmology, Kasr AlAiny Hospital, Cairo UniversityAbstract Aim To investigate the OCT macular changes in type 1 ROP one month following Ranibizumab injections. Methods Preterm infants with type 1 ROP indicated for Ranibizumab injections were included in this study. Handheld OCT imaging was performed at baseline, 1 week, and 1 month post injection. Central full thickness (CFT), inner retinal layer (IRL), and outer retinal layer (ORL) thickness measurements were taken from foveal center and parafoveal region. Results 24 eyes of 12 infants were included in this study. There were no significant changes in the mean CFT and IRL thickness at 1 month (p = 0.5 and 0.1 respectively). However, there was significant increase in the mean ORL thickness at 1 month (69.9 ± 16, 96.1 ± 25 at baseline and one month respectively, p < 0.001), with differentiation (appearance of IS/OS junction ± ELM) in 55.6% of eyes. Macular edema (ME) was observed in 12 eyes (50%) and was associated with smaller birth weight (p = 0.0290). There was no significant decrease in mean CFT in eyes with ME at 1 month (p = 0.13), with complete resolution in only 6 eyes (50%) during the study period. Regression of plus was associated with lower CFT (1 week and 1 month; p = 0.02 and 0.03, respectively). Conclusion Ranibizumab treated eyes in type 1 show ORL thickening and differentiation but with inadequate resolution of ME.https://doi.org/10.1186/s40942-025-00664-7Retinopathy of prematurityOCTIntravitreal RanibizumabMacular edema |
| spellingShingle | Rawan Hosny Jylan Gouda Tamer A. Macky Ayman Khattab Hany Mekkawy Abdussalam M. Abdullatif OCT macular changes in type 1 ROP following Ranibizumab injections International Journal of Retina and Vitreous Retinopathy of prematurity OCT Intravitreal Ranibizumab Macular edema |
| title | OCT macular changes in type 1 ROP following Ranibizumab injections |
| title_full | OCT macular changes in type 1 ROP following Ranibizumab injections |
| title_fullStr | OCT macular changes in type 1 ROP following Ranibizumab injections |
| title_full_unstemmed | OCT macular changes in type 1 ROP following Ranibizumab injections |
| title_short | OCT macular changes in type 1 ROP following Ranibizumab injections |
| title_sort | oct macular changes in type 1 rop following ranibizumab injections |
| topic | Retinopathy of prematurity OCT Intravitreal Ranibizumab Macular edema |
| url | https://doi.org/10.1186/s40942-025-00664-7 |
| work_keys_str_mv | AT rawanhosny octmacularchangesintype1ropfollowingranibizumabinjections AT jylangouda octmacularchangesintype1ropfollowingranibizumabinjections AT tameramacky octmacularchangesintype1ropfollowingranibizumabinjections AT aymankhattab octmacularchangesintype1ropfollowingranibizumabinjections AT hanymekkawy octmacularchangesintype1ropfollowingranibizumabinjections AT abdussalammabdullatif octmacularchangesintype1ropfollowingranibizumabinjections |